Preparation of Lipid Cubic Liquid Crystalline Nanoparticles of Sinomenine Based on Molecular Dynamics Simulations and Investigation of the Efficacy Against Rheumatoid Arthritis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110773 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jiaoyue Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China. Hauptthemen laut MEDLINE: Morphinans, Arthritis, Rheumatoid, Liquid Crystals, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changchun University of Chinese Medicine Golden Seed Program, the Science and Technology Development Program Project of Jilin Province, Science and Technology Development Program Project of Jilin Province.
Abstract (Originalsprache)
Sinomenine (SIN) is a promising candidate for the treatment of rheumatoid arthritis (RA). Although it possesses the advantage of being non-addictive, its poor aqueous solubility and low oral bioavailability have limited its clinical application. To address these issues, SIN was encapsulated into lipid cubic liquid crystal nanoparticles (LCNPs) and systematically characterized. Molecular dynamics (MD) simulations were first employed to screen suitable excipients for formulation development. Combined with single-factor optimization and Box–Behnken response surface design, the optimal composition and preparation process were determined. The resulting SIN-LCNPs exhibited a particle size of 149.7 ± 0.9 nm, a polydispersity index (PDI) of 0.223 ± 0.01, a zeta potential of −18.9 mV, and an encapsulation efficiency (EE%) of 92.2%. Spectroscopic analyses confirmed successful incorporation of SIN into the lipid matrix. Pharmacodynamic studies revealed that SIN-LCNPs enhanced targeted drug delivery to inflamed joints, significantly alleviating inflammation and suppressing disease progression in rats. In vivo single-pass intestinal perfusion (SPIP) experiments further demonstrated that SIN was primarily absorbed through the small intestine and that the LCNP carrier effectively improved its intestinal permeability. Collectively, this study provides a novel strategy and theoretical foundation for developing efficient formulations of poorly water-soluble drugs, highlighting the potential clinical application of SIN-LCNPs in RA therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China.
Förderung
- Changchun University of Chinese Medicine Golden Seed Program
- the Science and Technology Development Program Project of Jilin Province
- Science and Technology Development Program Project of Jilin Province
Zitieren
APA
Zhu, J., Li, J., Zou, Y., Ding, X., Li, J., Xu, J., Xiao, Y., Qiu, Y., & Xu, W. (2025). Preparation of Lipid Cubic Liquid Crystalline Nanoparticles of Sinomenine Based on Molecular Dynamics Simulations and Investigation of the Efficacy Against Rheumatoid Arthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110773
Vancouver
Zhu J, Li J, Zou Y, Ding X, Li J, Xu J, et al. Preparation of Lipid Cubic Liquid Crystalline Nanoparticles of Sinomenine Based on Molecular Dynamics Simulations and Investigation of the Efficacy Against Rheumatoid Arthritis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110773
BibTeX
@article{Zhu2025,
author = {Zhu, Jiaoyue and Li, Jingying and Zou, Yunlu and Ding, Xuehui and Li, Jixin and Xu, Jiahui and Xiao, Yinghao and Qiu, Ye and Xu, Wei},
title = {Preparation of Lipid Cubic Liquid Crystalline Nanoparticles of Sinomenine Based on Molecular Dynamics Simulations and Investigation of the Efficacy Against Rheumatoid Arthritis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110773}
}
EUVIMED